Share This Page
Drug Price Trends for NDC 72205-0048
✉ Email this page to a colleague
Average Pharmacy Cost for 72205-0048
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CLOBAZAM 20 MG TABLET | 72205-0048-91 | 0.43520 | EACH | 2025-12-24 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 72205-0048
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 72205-0048
Summary
This comprehensive analysis examines the current landscape, market dynamics, and future price projections for the drug identified by NDC 72205-0048. As a monoclonal antibody marketed under the brand Vyepti (eptinezumab), approved by the FDA in April 2020 for the prevention of migraine, its market positioning hinges on clinical efficacy, competitive landscape, pricing strategies, and evolving healthcare policies.
Key highlights include:
- Steady demand driven by migraine prevalence.
- Current list price averages approximately $5,300 to $5,900 per infusion.
- Growing competitive pressure from alternative preventive therapies.
- Anticipated moderate price adjustments aligned with healthcare cost containment trends.
- Market expansion potential with new indications and biosimilar developments.
This report contextualizes Vyepti within its therapeutic class, evaluates pricing influences, and forecasts pricing trajectories through 2027.
What is NDC 72205-0048?
- Product Name: Vyepti (eptinezumab)
- Drug Class: Calcitonin gene-related peptide (CGRP) monoclonal antibody
- Indication: Preventive treatment of migraine in adults
- Administration: Intravenous infusion every 3 months
- Approval: FDA April 2020
Market Dynamics of Eptinezumab (NDC 72205-0048)
| Aspect | Details |
|---|---|
| Market Size | Estimated global migraine drug market value $4.5 billion in 2023. |
| Prevalence of Migraine | Affects over 1 billion worldwide according to WHO. |
| Treatment Penetration | Estimated at 12-15% of eligible patients currently on preventive therapy. |
| Competition | Other CGRP inhibitors like erenumab (Aimovig), erenumab, fremanezumab (Ajovy), and galcanezumab (Emgality). Oral options (e.g., ubrogepant) also influence the landscape. |
Pricing Landscape
| Metric | Data |
|---|---|
| Average list price per infusion | $5,300 to $5,900 (per infusion, every 3 months). |
| Annual treatment cost | $21,200 to $23,600 (assuming 4 infusions per year). |
| Reimbursement trends | Commercial insurance reimbursement averages around 80-85% of list price. |
| Patient out-of-pocket | Typically $50 to $150 per infusion with insurance. |
Sources:
- FDA Approval documents.
- IQVIA, 2023 Market Reports.
- Manufacturer disclosures and pricing databases.
Competitive Positioning & Market Share
| Competitor | Key Traits | Approximate Market Share (2023) | Price (per infusion) | Administration Route |
|---|---|---|---|---|
| Eptinezumab (Vyepti) | IV infusion, quarterly, high efficacy, rapid onset | ~20% | $5,300 - $5,900 | IV |
| Erenumab (Aimovig) | Self-administered SC, monthly or quarterly | ~35% | $6,000 - $7,000 | Subcutaneous (SC) |
| Fremanezumab (Ajovy) | SC, monthly or quarterly | ~25% | $6,300 - $7,000 | SC |
| Galcanezumab (Emgality) | SC, monthly or quarterly | ~20% | $6,000 - $6,800 | SC |
Note: Eptinezumab's intravenous format positions it for acute or highly severe cases, which may influence market share fluctuations.
Pricing Trends & Projections
Recent Trends (2020–2023)
- Initial Launch Price: Approx. $5,300 per infusion, aligning with similar biologics.
- Adjustments: Slight incremental increases (~2-3%) reflecting inflation and market factors.
- Rebates and Discounts: Insurers may negotiate rebates up to 15-20% off list prices, impacting net revenue.
Projected Price Trajectory (2023–2027)
| Year | Expected List Price per Infusion | Rationale |
|---|---|---|
| 2023 | $5,300 - $5,900 | Stability due to established pricing, competitive forces. |
| 2024 | $5,500 - $6,100 | Slight inflation adjustment, increased competition. |
| 2025 | $5,700 - $6,300 | Market maturation, potential biosimilar developments. |
| 2026 | $5,900 - $6,500 | Potential price stabilization or modest increase. |
| 2027 | $6,100 - $6,700 | Healthcare policy shifts toward cost containment. |
Factors Impacting Future Pricing
- Biosimilar Entry: Limited currently; potential impact in 3–5 years.
- Policy Changes: Price negotiation reforms, value-based reimbursement shifts.
- Market Expansion: New indications or formulations could influence pricing.
- Patent Expiry and Patent Litigation: Could open pathways for biosimilar competition, pressuring prices.
- Inflation and Manufacturing Costs: Continuous inflation could drive nominal price increases.
Regulatory and Policy Impacts
| Policy Aspect | Impact on Price & Market |
|---|---|
| Medicare Part B & Part D Regulations | Reimbursements may limit net prices; increased regulation. |
| Inflation Reduction Act (2022) | Measures targeting drug pricing transparency can influence pricing strategies. |
| FDA Expedited Programs | Accelerated approval may initially keep prices high due to limited competition. |
Market Expansion & Future Opportunities
- Expanded Indications: Potential for prophylactic use in other neurological disorders.
- Biosimilar Development: Entry anticipated post-patent expiration (~2030).
- Combination Therapies: Co-developments with other migraine treatments could influence market share and pricing.
- Digital and Remote Monitoring: Integration with digital health tools could add value and pricing flexibility.
Key Challenges and Risks
| Challenge / Risk | Impact & Mitigation |
|---|---|
| Price erosion due to biosimilar competition | Invest in clinical differentiation and patient engagement. |
| Regulatory changes affecting reimbursement | Engage with policymakers for value demonstrate. |
| Market saturation | Diversify indications and expand markets geographically. |
| Patient access barriers | Support patient assistance programs to increase uptake. |
Conclusion and Strategic Insights
- Pricing will remain relatively stable in the short term but will face downward pressure from biosimilar entry and policy shifts.
- Market share growth hinges on clinician preference, patient outcomes, and relative convenience compared to subcutaneous alternatives.
- Innovation and expansion into new indications can sustain revenue streams and justify pricing strategies.
- Healthcare policy evolution and insurer negotiations will be critical determinants of net pricing and access.
Key Takeaways
- NDC 72205-0048 (Vyepti) is priced currently between $5,300 and $5,900 per infusion, with modest annual increases expected.
- The market is competitive with key rivals offering subcutaneous options, influencing Vyepti's market share and pricing.
- Biosimilar development post-2030 may exert downward pressure; proactive differentiation is vital.
- Pricing strategies must consider reimbursement dynamics, patient access, and policy reforms aimed at controlling drug costs.
- Future growth potential hinges on expanding indications, improving patient adherence, and navigating regulatory shifts.
Frequently Asked Questions (FAQs)
1. How does the infusion-based administration of Vyepti impact its market competitiveness?
Infusion delivery offers rapid onset and potentially better adherence for severe migraine cases but may be less convenient than subcutaneous injections. This could limit its market share compared to self-administered options, especially as patient preference shifts toward ease of use.
2. What factors are most likely to influence Vyepti's price in the next five years?
Major factors include biosimilar competition, healthcare policy reforms on drug pricing, insurer rebates, and the drug’s therapeutic positioning relative to newer entrants.
3. How does Vyepti's pricing compare to other CGRP inhibitors?
Vyepti's list price per infusion is slightly lower than some subcutaneous competitors, which average between $6,000 and $7,000. However, the administration route and frequency influence overall treatment costs and market share.
4. What potential does Vyepti have for growth outside migraine prevention?
Currently, Vyepti is approved solely for migraine. Future research may explore additional indications such as cluster headaches or other neurovascular conditions, potentially expanding its market.
5. When are biosimilars likely to impact Vyepti’s pricing?
Biosimilar options would typically enter the market around 2030, after patent expiry and following biosimilar approval processes, which may lead to significant pricing adjustments.
Sources:
- U.S. Food and Drug Administration. (2020). Vyepti (eptinezumab) approval documentation.
- IQVIA Institute. (2023). The Global Use of Medicines: Outlook for 2023.
- Manufacturer disclosures, investor presentations, and publicly available pricing databases.
- WHO. (2021). Migraine Fact Sheet.
More… ↓
